Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer

INTRODUCTION: Enzalutamide is an oral androgen receptor (AR) signaling inhibitor that was specifically engineered to overcome castration-resistant prostate cancer (CRPC) harboring AR amplification or overexpression. Enzalutamide has demonstrated significant activity in men with metastatic CRPC. AIMS...

Descripción completa

Detalles Bibliográficos
Autores principales: Golshayan, Ali R, Antonarakis, Emmanuel S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622394/
https://www.ncbi.nlm.nih.gov/pubmed/23589709
http://dx.doi.org/10.2147/CE.S34747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3622394/
https://www.ncbi.nlm.nih.gov/pubmed/23589709
http://dx.doi.org/10.2147/CE.S34747

Ejemplares similares